| Autor: |
Garzon AM; Department of Pediatrics, Memorial Sloan Kettering Cancer Center , New York, NY , USA., Mitchell WB; Laboratory of Platelet Biology, New York Blood Center , New York, NY , USA ; Division of Pediatric Hematology Oncology, Weill Cornell Medical College , New York, NY , USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Frontiers in pediatrics [Front Pediatr] 2015 Aug 13; Vol. 3, pp. 70. Date of Electronic Publication: 2015 Aug 13 (Print Publication: 2015). |
| DOI: |
10.3389/fped.2015.00070 |
| Abstrakt: |
Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go on to have chronic ITP. In those children with chronic ITP who need treatment, standard therapies for acute ITP may have adverse effects that complicate their long-term use. Thus, alternative treatment options are needed for children with chronic ITP. Thrombopoietin receptor agonists (TPO-RA) have been shown to be safe and efficacious in adults with ITP, and represent a new treatment option for children with chronic ITP. One TPO-RA, eltrombopag, is now approved for children. Clinical trials in children are ongoing and data are emerging on safety and efficacy. This review will focus on the physiology of TPO-RA, their clinical use in children, as well as the long-term safety issues that need to be considered when using these agents. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
